From scientific complexity to market execution.

A 2026 Science study uses CRISPR TAPIR to increase rRNA transcription and asks whether translation capacity itself can shape stem cell fate, linking ribosome biology with regeneration, ribosomopathies, and cancer.

Four ISSCR 2026 keynotes point to one conclusion: gene delivery is the real bottleneck in cell and gene therapy. What it means for CMC, CDMOs, and capital.

Executive Summary If you only have three minutes to read this article, here are five key takeaways: Aging is increasingly viewed as a biological process that can potentially be modified, rather than an inevitable consequence of time. The discovery of the Yamanaka Factors revolutionized modern biology by demonstrating that cell identity is reversible, leading to the development of induced pluripotent stem cells (iPSCs). Today, the most exciting direction in aging research is P

Figure 1. Evolution from autologous to off-the-shelf cell therapy. Comparison of autologous and allogeneic cell therapy manufacturing workflows. Unlike patient-specific manufacturing, iPSC-derived allogeneic therapies leverage Master Cell Banks (MCBs), standardized manufacturing processes, and large-scale production to enable scalable, off-the-shelf regenerative medicine. Executive Summary Key Takeaways Induced pluripotent stem cells (iPSCs) have evolved from a stem cell tech

Figure 1. The Journey of Induced Pluripotent Stem Cells (iPSCs): From Somatic Cell Reprogramming to Regenerative Medicine. Adult somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs), expanded and banked, differentiated into specialized cell types, and applied in disease modeling, drug discovery, regenerative medicine, and cell therapy. This workflow highlights how iPSCs serve as a foundational platform technology connecting basic research with transla

Introduction: For the First Time, Treatment Is About More Than Controlling Blood Sugar For more than a century, the treatment of Type 1 Diabetes (T1D) has been relatively straightforward. If the body cannot produce insulin, we replace insulin. This approach has saved millions of lives since the discovery of insulin in 1921. However, if we look deeper, one important fact becomes apparent: We have never truly addressed the underlying disease. The problem is not simply a lack of